Veliparib (ABT-888): A Potent PARP Inhibitor for Advanced Research
Discover Veliparib (ABT-888), a leading PARP-1/-2 inhibitor that significantly potentiates the effects of DNA-damaging agents in oncology research. Learn about its applications, mechanism, and secure reliable supply from our expert manufacturer.
Get a Quote & SampleUnlocking Cancer Treatment Potential with Veliparib
Veliparib (ABT-888)
As a premier manufacturer and supplier, we offer high-purity Veliparib (ABT-888), a critical compound for researchers in oncology. This potent inhibitor of PARP-1 and PARP-2 enzymes plays a vital role in cancer therapy by blocking DNA repair mechanisms, making cancer cells more susceptible to treatments. Explore our competitive price and ensure a stable supply for your groundbreaking research.
- Potent PARP-1/-2 Inhibition: Crucial for understanding DNA repair pathways and developing targeted cancer therapies.
- Enhanced Chemotherapy Efficacy: Veliparib potentiates the effects of DNA-damaging agents like temozolomide and carboplatin.
- Research Applications: Widely used to study synthetic lethality, autophagy, and apoptosis in cancer cell lines.
- Quality Assurance: Sourced from a trusted China-based manufacturer, ensuring high purity and batch-to-batch consistency for reliable experimental results.
Key Advantages of Sourcing Veliparib
Superior Inhibition Potency
With Ki values of 5.2 nM for PARP-1 and 2.9 nM for PARP-2, Veliparib offers exceptional potency, making it a preferred choice for demanding research applications in DNA damage response.
Broad Spectrum of Efficacy
Veliparib's ability to increase autophagy and apoptosis, and its compatibility with various cancer therapies, makes it an indispensable tool for scientists exploring novel combination treatments.
Reliable Global Supply Chain
As a dedicated supplier, we ensure a consistent and timely supply of Veliparib, supporting your ongoing research projects without interruption. Inquire about our competitive pricing and bulk purchase options.
Applications in Advanced Cancer Research
Oncology Drug Development
Veliparib is a key compound in the development of new anticancer drugs, particularly those targeting DNA repair mechanisms and synthetic lethality.
Mechanism of Action Studies
Facilitates research into how PARP inhibition affects DNA damage, cell cycle progression, and overall cellular response to genotoxic stress.
Combination Therapy Research
Investigate the synergistic effects of Veliparib with chemotherapy, radiation therapy, and other targeted agents to enhance treatment outcomes.
Biomarker Discovery
Used in studies to identify biomarkers that predict patient response to PARP inhibitors, crucial for personalized medicine in oncology.